Literature DB >> 15681708

Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure.

Karni S Moshal1, Neetu Tyagi, Brooke Henderson, Alexander V Ovechkin, Suresh C Tyagi.   

Abstract

We examined the hypothesis that oxidants generated nitroso derivatives, activated latent matrix metalloproteinase (MMP), and induced proteinase-activated receptor 1 (PAR-1), leading to disconnection between the endothelium and myocytes. Administration of cardiospecific tissue inhibitor of metalloproteinase-4 (TIMP-4/CIMP) ameliorated the oxidative-proteolytic stress and endothelial-myocyte uncoupling in chronic heart failure (CHF) in mice. Aortic-vena cava fistula (AVF) was created in 30 male mice (C57BL/6J) and studied at 0-, 2-, and 8-wk AVF. To reverse cardiac remodeling, as measured by MMP activation, purified CIMP was administered by an osmotic minipump subcutaneously after 8-wk AVF, and groups of mice (n = 6 mice/group) were examined after 12 and 16 wk. Levels of PAR-1 in the left ventricle (LV) were increased at 2 and 8 wk (compared with 0 wk of no CIMP treatment) but were normal at 12 and 16 wk after CIMP treatment, as measured by Western blot analysis. Similar results were obtained for LV levels of nitrotyrosine, MMP-2 and -9 activities, and TIMP-1 and -3. However, the levels of TIMP-4, endothelial cell density, and responses of cardiac rings to acetylcholine and bradykinin were attenuated at 2 and 8 wk and normalized after CIMP administration in AVF mice. CIMP induced nitric oxide in microvascular endocardial endothelial cells. The results suggest that nitro generation activated MMP and PAR-1, leading to endothelial-myocyte uncoupling. CIMP treatment normalized PAR-1 expression and ameliorated endothelial-myocyte uncoupling by decreasing oxidant-mediated proteolytic stress in CHF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681708     DOI: 10.1152/ajpheart.01146.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  18 in total

1.  Mesenteric vascular remodeling in hyperhomocysteinemia.

Authors:  C Munjal; S Givvimani; N Qipshidze; N Tyagi; J C Falcone; S C Tyagi
Journal:  Mol Cell Biochem       Date:  2010-11-13       Impact factor: 3.396

Review 2.  Arrhythmia and neuronal/endothelial myocyte uncoupling in hyperhomocysteinemia.

Authors:  Dorothea Rosenberger; Karni S Moshal; Ganesh K Kartha; Neetu Tyagi; Utpal Sen; David Lominadze; Claudio Maldonado; Andrew M Roberts; Suresh C Tyagi
Journal:  Arch Physiol Biochem       Date:  2006 Oct-Dec       Impact factor: 4.076

3.  3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice.

Authors:  Alexander V Ovechkin; Neetu Tyagi; Utpal Sen; David Lominadze; Mesia M Steed; Karni S Moshal; Suresh C Tyagi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06-30       Impact factor: 5.464

4.  Effects of thrombin and thrombin receptor activation on cardiac function after acute myocardial infarction.

Authors:  Xinyuan Gu; Xiaorong Zhang; Guihua Lu; Yanhui Li; Xiujuan Li; He Huang; Jianping Zeng; Lilong Tang
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

Review 5.  Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling.

Authors:  Thomas P Vacek; Jonathan C Vacek; Suresh C Tyagi
Journal:  Arch Physiol Biochem       Date:  2011-12-19       Impact factor: 4.076

6.  Synergism between arrhythmia and hyperhomo-cysteinemia in structural heart disease.

Authors:  Srikanth Givvimani; Natia Qipshidze; Neetu Tyagi; Paras K Mishra; Utpal Sen; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-05-29

7.  MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA.

Authors:  Paras Kumar Mishra; Naira Metreveli; Suresh C Tyagi
Journal:  Cell Biochem Biophys       Date:  2010-07       Impact factor: 2.194

8.  PAR1-dependent COX-2/PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes.

Authors:  Peter Tzu-Yu Chien; Hsi-Lung Hsieh; Pei-Ling Chi; Chuen-Mao Yang
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

9.  Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts.

Authors:  Dmitry L Sonin; Tetsuro Wakatsuki; Kasi V Routhu; Leanne M Harmann; Matthew Petersen; Jennifer Meyer; Jennifer L Strande
Journal:  J Cardiovasc Pharmacol Ther       Date:  2013-04-17       Impact factor: 2.457

10.  Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy.

Authors:  Rafal Pawlinski; Michael Tencati; Craig R Hampton; Tetsuro Shishido; Tara A Bullard; Liam M Casey; Patricia Andrade-Gordon; Matthias Kotzsch; Denise Spring; Thomas Luther; Jun-ichi Abe; Timothy H Pohlman; Edward D Verrier; Burns C Blaxall; Nigel Mackman
Journal:  Circulation       Date:  2007-10-29       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.